 Grade 3 reversible liver transaminase elevations were reported.The maximum tolerated dose was 900 mg/day.NQO1 mRNA levels, indicative of Nrf2 pathway activation, were increased in peripheral blood mononuclear cells (PBMCs), and tumor biopsies showed decreased levels of NF-κB and cyclin D1.